Stocks Rotation Con...
Health Care: Drugs
Incyte Corp Ltd (INCY: NASDAQ)
$17.42 -0.54 | -3.01%
02/08/12 - 04:00 PM ET
1.73M / 2.13M
Vol / Avg. Vol:17.95 / 17.96
Open / Prev. Close:16.92 - 17.99
Today's Range:11.76 - 21.15
52 Wk Range:16.06%
Performance YTD:TheStreet Rating:
Portfolios with INCY
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
- Contributor10 Biotech Stocks Loved and...
- ContributorHot Biotech Trades for Seco...
- Contributor4 Small-Cap Stocks Made for...
- ContributorCancer Drug Stocks to Trade...
- Contributor10 Pharma Stocks With Upside
- Userjbrookmon
Latest INCY Headlines from TheStreet
- 8 Stocks Rising on Monster Volume 01.23.12 | 04:01 pm
- Insiders Trading INCY, LOPE, STMP, HMA 01.23.12 | 09:01 am
- 5 Stocks Flashing 'Buy' Alerts 01.19.12 | 06:01 pm
- Insiders Trading INCY, APOL, GEOY, MSM 01.18.12 | 09:01 am
- Incyte CEO Presents At 30th Annual JP Morgan Healthcare Conference (Transcript) 01.09.12 | 04:01 pm
- YM Bio's Myelofibrosis Drug Is For Real 12.12.11 | 06:12 pm
- 7 Stocks Rising on Unusual Volume 12.12.11 | 12:12 pm
- Onyx Trips, Ariad and Pharmacyclics Shine at Blood Cancer Meeting 12.12.11 | 07:12 am
- Biotech Stock Mailbag: YM Bio, Exact, Peregrine 12.09.11 | 06:12 am
- Insiders Trading INCY, BBEP, WMGI, PLOW 12.02.11 | 09:12 am
Press Releases for INCY
- Incyte To Present At The Leerink Swann 2012 Global Healthcare Conference - Business Wire 02.03.12 | 08:02 am
- Incyte To Report Fourth Quarter/Year-End 2011 Financial Results On February 15 - Business Wire 01.26.12 | 04:01 pm
- Incyte To Present At The 30th Annual J. P. Morgan Healthcare Conference - Business Wire 12.20.11 | 04:12 pm
- First FDA-Approved Treatment For Myelofibrosis, Jakafi™ (ruxolitinib), Discussed In Multiple Presentations At 2011 ASH Annual Meeting - Business Wire 12.12.11 | 08:12 am
- Incyte To Present At The Oppenheimer & Co. 22nd Annual Healthcare Conference - Business Wire 11.30.11 | 04:11 pm
- Incyte To Present At The 23rd Annual Piper Jaffray Health Care Conference - Business Wire 11.18.11 | 08:11 am
- Jakafi(TM) (ruxolitinib) Is The First And Only Product To Be Approved By The FDA For Myelofibrosis, And The First In A New Class Of Drugs, Known As JAK Inhibitors, To Be Approved For Any Indication. (Photo: Business Wire) - Business Wire 11.16.11 | 11:11 am
- Incyte Reports Third Quarter 2011 Financial Results And Provides Update On Key Clinical Programs - Business Wire 10.27.11 | 07:10 am
- Incyte To Report Third Quarter 2011 Financial Results And Provide Update On Key Clinical Programs On October 27 - Business Wire 10.13.11 | 04:10 pm
- Incyte To Present At Upcoming Investor Conferences - Business Wire 08.30.11 | 04:08 pm
Partner Headlines for INCY
- 10 Biotech Stocks With Strong Corporate Governance - Seeking Alpha 01.18.12 | 09:01 am
- Steve Cohen And Insiders Are Bullish About These Stocks - Seeking Alpha 01.12.12 | 09:01 am
- Biotech Investors Buoyed By Signs Of Speedier Drug Launches - Seeking Alpha 01.09.12 | 08:01 am
- YM's Positive Results Have Incyte Investors Worried - Seeking Alpha 12.15.11 | 09:12 am
- Noteworthy Insider Buys In The Healthcare Sector Last Week - Seeking Alpha 11.29.11 | 08:11 am
- Incyte JAK Inhibitor Awaits Certain Approval - Seeking Alpha 11.14.11 | 09:11 am
- Risk-Reward Balanced at Incyte - Analyst Blog - Zacks 06.15.11 | 07:06 pm
- Incyte, Novartis myelofibrosis trial meets goal - Reuters 06.04.11 | 02:06 pm
- Upgrades, Downgrades and Initiations for Thursday - Seeking Alpha 06.02.11 | 09:06 am
- Drugs to Watch at ASCO 2011 - Seeking Alpha 06.02.11 | 08:06 am
